[{"id":"3bb3cbaf-b275-4098-8e50-b212d3de0ff5","acronym":"cRIB","url":"https://clinicaltrials.gov/study/NCT05645718","created_at":"2022-12-09T14:57:54.671Z","updated_at":"2024-07-02T16:35:06.157Z","phase":"Phase 2","brief_title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT05645718 - cRIB","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • Neulasta (pegfilgrastim) • Depocyte (liposomal cytarabine)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-05-03"},{"id":"4e9aa552-a12c-4da8-8240-a354eef4c428","acronym":"","url":"https://clinicaltrials.gov/study/NCT00968760","created_at":"2021-01-18T03:46:34.880Z","updated_at":"2024-07-02T16:35:25.752Z","phase":"Phase 1","brief_title":"CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies","source_id_and_acronym":"NCT00968760","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan • Proleukin (aldesleukin) • Depocyte (liposomal cytarabine)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 04/23/2020","primary_completion_date":" 04/23/2020","study_txt":" Completion: 04/23/2020","study_completion_date":" 04/23/2020","last_update_posted":"2023-12-19"},{"id":"d2f28e68-db4b-42b9-85cb-b34ffca07748","acronym":"","url":"https://clinicaltrials.gov/study/NCT03125642","created_at":"2021-01-18T15:23:59.295Z","updated_at":"2024-07-02T16:35:30.655Z","phase":"Phase 2","brief_title":"Auto Stem Cell Transplant for Lymphoma Patients","source_id_and_acronym":"NCT03125642","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" ALK • CD4 • TCL1A","pipe":" | ","alterations":" ALK positive","tags":["ALK • CD4 • TCL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Depocyte (liposomal cytarabine) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/20/2017","start_date":" 04/20/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-11-02"},{"id":"d66d264b-f1b4-4b9d-a8e5-a0062a91f59e","acronym":"O-ICE","url":"https://clinicaltrials.gov/study/NCT02393157","created_at":"2021-01-18T11:24:47.737Z","updated_at":"2024-07-02T16:35:31.507Z","phase":"Phase 2","brief_title":"Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL","source_id_and_acronym":"NCT02393157 - O-ICE","lead_sponsor":"New York Medical College","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Depocyte (liposomal cytarabine)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/21/2015","start_date":" 08/21/2015","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-26"},{"id":"7b5137ef-a094-4655-a719-18b9e514cbf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01859819","created_at":"2021-01-17T17:32:29.842Z","updated_at":"2024-07-02T16:36:01.864Z","phase":"Phase 2","brief_title":"Treatment for Advanced B-Cell Lymphoma","source_id_and_acronym":"NCT01859819","lead_sponsor":"New York Medical College","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Depocyte (liposomal cytarabine)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2022-10-25"},{"id":"766481ec-fdf8-471f-84d7-c6eb79462b60","acronym":"","url":"https://clinicaltrials.gov/study/NCT00591630","created_at":"2021-01-18T02:11:23.277Z","updated_at":"2024-07-02T16:36:35.173Z","phase":"Phase 2","brief_title":"Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation","source_id_and_acronym":"NCT00591630","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20 • CD34","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • etoposide IV • carmustine • melphalan • Zevalin (ibritumomab tiuxetan) • Depocyte (liposomal cytarabine)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 11/14/2007","start_date":" 11/14/2007","primary_txt":" Primary completion: 03/05/2020","primary_completion_date":" 03/05/2020","study_txt":" Completion: 03/05/2020","study_completion_date":" 03/05/2020","last_update_posted":"2021-02-02"},{"id":"e0854a67-8b83-41a5-a3f8-45934f25242c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00536978","created_at":"2021-01-18T01:56:59.877Z","updated_at":"2024-07-02T16:36:40.726Z","phase":"Phase 2","brief_title":"Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies","source_id_and_acronym":"NCT00536978","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 negative","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • Campath (alemtuzumab) • carmustine • melphalan • fludarabine IV • Depocyte (liposomal cytarabine) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 11/01/2010","study_completion_date":" 11/01/2010","last_update_posted":"2020-09-24"},{"id":"a033d9f2-b1be-4d3f-926c-ced213a7a05a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00290433","created_at":"2021-01-18T00:59:21.701Z","updated_at":"2024-07-02T16:36:40.765Z","phase":"Phase 2","brief_title":"Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT00290433","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8 • ALK1","pipe":"","alterations":" ","tags":["TNFRSF8 • ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • dexamethasone • mesna • Depocyte (liposomal cytarabine) • Neupogen (filgrastim) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 09/01/2003","start_date":" 09/01/2003","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 07/01/2015","study_completion_date":" 07/01/2015","last_update_posted":"2020-09-23"},{"id":"5d234368-124f-42e0-9f75-432dd0b9a497","acronym":"","url":"https://clinicaltrials.gov/study/NCT00345865","created_at":"2021-01-29T06:56:20.327Z","updated_at":"2024-07-02T16:36:43.292Z","phase":"Phase 2","brief_title":"Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma","source_id_and_acronym":"NCT00345865","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Depocyte (liposomal cytarabine) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 473","initiation":"Initiation: 08/24/2005","start_date":" 08/24/2005","primary_txt":" Primary completion: 06/28/2019","primary_completion_date":" 06/28/2019","study_txt":" Completion: 06/28/2019","study_completion_date":" 06/28/2019","last_update_posted":"2020-07-14"},{"id":"84a04cf0-e252-4987-a4ce-7095582ae74e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01325194","created_at":"2021-01-18T05:23:48.487Z","updated_at":"2024-07-02T16:36:49.334Z","phase":"Phase 2","brief_title":"CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis","source_id_and_acronym":"NCT01325194","lead_sponsor":"Nordic Lymphoma Group","biomarkers":" CD20","pipe":" | ","alterations":" LDH elevation","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Depocyte (liposomal cytarabine)"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2020-03-03"},{"id":"a43f49ed-0945-45fd-8880-0a0afe3367ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT00553943","created_at":"2021-01-18T02:01:05.953Z","updated_at":"2024-07-02T16:37:07.547Z","phase":"Phase 2","brief_title":"Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis","source_id_and_acronym":"NCT00553943","lead_sponsor":"Lymphoma Study Association","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Depocyte (liposomal cytarabine)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 07/01/2007","start_date":" 07/01/2007","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2018-08-23"},{"id":"9e3d8f1b-a521-4353-a085-fa222ff26efb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02680951","created_at":"2021-01-18T13:04:24.331Z","updated_at":"2024-07-02T16:37:11.385Z","phase":"Phase 1","brief_title":"Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia","source_id_and_acronym":"NCT02680951","lead_sponsor":"Emory University","biomarkers":" KIT • STAT3","pipe":" | ","alterations":" KIT expression","tags":["KIT • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • idarubicin hydrochloride • fludarabine IV • Depocyte (liposomal cytarabine)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 12/15/2017","primary_completion_date":" 12/15/2017","study_txt":" Completion: 12/15/2017","study_completion_date":" 12/15/2017","last_update_posted":"2018-04-19"},{"id":"5c2a1e5c-1536-4a08-af7c-14f102e0dc21","acronym":"","url":"https://clinicaltrials.gov/study/NCT00073957","created_at":"2021-01-18T00:11:41.115Z","updated_at":"2024-07-02T16:37:14.601Z","phase":"Phase 2","brief_title":"Y 90 Ibritumomab Tiuxetan \u0026Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00073957","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan) • Depocyte (liposomal cytarabine)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/01/2003","start_date":" 12/01/2003","primary_txt":" Primary completion: 01/01/2012","primary_completion_date":" 01/01/2012","study_txt":" Completion: 01/01/2012","study_completion_date":" 01/01/2012","last_update_posted":"2018-01-23"},{"id":"da35062e-384e-4dbb-94cd-bedee3db4566","acronym":"","url":"https://clinicaltrials.gov/study/NCT01756677","created_at":"2021-01-18T07:42:59.855Z","updated_at":"2024-07-02T16:37:17.320Z","phase":"Phase 1/2","brief_title":"Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients","source_id_and_acronym":"NCT01756677","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cytarabine • Actimab-A (lintuzumab-Ac225) • Depocyte (liposomal cytarabine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-04"}]